Current status of blood pressure control in patients with coronary heart disease

doi:10.12047/j.cjap.5599.2018.007

Abstract

Abstract: Objective: To evaluate the level of blood pressure control in patients with coronary heart disease (CHD) of China in order to provide guidance for the prevention and treatment of CHD.Methods: The patients with CHD were retrospectively collected from 2011~2014 in PLA General Hospital and Hainan Branch Hospital. Then analyzed the difference of blood pressure compliance rate between different surgical methods percutaneous coronary intervention (PCI), coronary artery bypass grafting(CABG), secondary preventive drugs(aspirin, clopidogrel, nitrates, trimetazidine, nicorandil, hypotensor, hypoglycemic, lipid-lowering drugs) and lifestyle(smoking, drinking, exercise).Results: ①Effects of surgical methods on blood pressure:Male's systolic blood pressure (SBP) and diastolic blood pressure(DBP) in the CABG group were lower in the PCI group and control group, and female's DBP in the CABG group were lower in the PCI group. ②Usage rate of secondary prevention drugs:usage rate of trimetazidine, calcium antagonist, β-blockers, angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) in hypertension group were higher than in normal blood pressure group. ③ Lifestyle condition:compliance rate of blood pressure in the smoking group was lower than that in the non smoking group. And there was no significant difference in blood pressure compliance rate among whether drinking and doing exercise or not.Conclusion: Blood pressure control in patients with CHD was still not satisfied. Compared with PCI, CABG may be more beneficial in the control of blood pressure in patients with CHD. Smoking cessation and improving the usage rate of secondary preventive drugs are still the main means of blood pressure control.

Key words: coronary heart disease, hypertension, PCI, CABG, drug, lifestyle, secondary prevention

ZHANG Yue, WANG Tian-tian, GUO Shu-li, HAN Li-na, ZHANG Li, LI Xiao-ying, FAN Jin. Current status of blood pressure control in patients with coronary heart disease[J]. CJAP, 2018, 34(1): 23-27.

References

[1] Go AS, Mozaffarian D, Roger VL, et al. Executive Summary:Heart Disease and Stroke Statistics-2014 Update[J]. Circulation, 2014, 129(3):339-410.
[2] 中国高血压防治指南修订委员会. 中国高血压防治指南(2005修订版)[J]. 北京:人民卫生出版社, 2005:1-30.
[3] Yang FB, Guo WL, Sheng M, et al. Diagnostic accuracy of coronary angiography using 64-slice computed tomography in coronary artery disease[J]. Saudi Med, 2015, 36(10):1156-1162.
[4] 李小鹰, 王林, 于普林, 等. 老年人冠心病治疗与二级预防现状调查[J]. 中华老年医学杂志, 2012, 31(10):909-914.
[5] Kulik A. Secondary prevention after coronary artery bypass graft surgery[J]. Curr Opin Cardiol, 2016, 31(6):635-643.
[6] Gyárfás I, Keltai M, Salim Y. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study[J]. Orv Hetil, 2006, 47(15):675-86.
[7] Crithley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with CHD:A systematic review[J]. JAMA, 2003, 290(1):86-97.
[8] 丁荣晶, 吕安康, 胡大一, 等. 心血管病患者戒烟处方中国专家共识[J]. 中华心血管病杂志, 2013, 9(41Suppl 1):9-16.
[9] Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium[J]. BMJ, 2015, 350:h1551.
[10] Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study):a prospective epidemiologyical survey[J]. Lancet, 2011, 378(9798):1231-1243.
[11] 胡大一, 丁荣晶, 刘遂心, 等. 冠心病康复与二级预防中国专家共识. 中华心血管病杂志, 2013, 41(4):267-275.
[12] Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease:a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention[J]. Circulation, 2007, 115(21):2761-2788.

[1]	DONG De-gang, YU Zhi-da, YU Zhong-shun. Effects of Fitness Qigong Baduanjin on phlegm-dampness hypertension [J]. CJAP, 2020, 36(2): 157-160.
[2]	DOU Li. Effects of swimming training on blood pressure and prethrombotic state molecules in hypertensive rats [J]. CJAP, 2020, 36(2): 161-164.
[3]	WANG Ya-feng, WANG Ai-xia, WANG Sheng-biao, DUO De-long, LI Qian, YAN Ying-jun. Effects of Salvia przewalskii Maxim. on high-altitude pulmonary hypertension in rats and its mechanism [J]. CJAP, 2019, 35(6): 533-536.
[4]	ZHANG Wen-fei, YANG Chang-zhen, HU Peng-cheng, CHEN Hao, XI Yue, FAN Hong-kun, ZHANG Qian, YANG Chun. The changes of the expression of 2-type small conductance-Ca²⁺- activating-K⁺ (SK2) channel protein in hypertensive rat myocardium [J]. CJAP, 2019, 35(4): 381-384.
[5]	ZHANG Shu-hao, SHAO Si-ming, CHEN Fang-zheng, ZHU Jing, CHEN Luo-wei, WANG heng, XIANG Xin-hui, YUAN Lin-bo. Effects of apple polyphenols on monocrotaline-induced pulmonary vascular remodeling in rats and its mechanism [J]. CJAP, 2019, 35(3): 209-214.
[6]	LEI Yong-fu, LI Min. The correlation between the carotid artery plaque and the change of aldosterone level related indexes during captopril challenge test [J]. CJAP, 2019, 35(1): 85-89.
[7]	LIU Ling-yan, HUANG Tian-peng, HAO Jia-le, CHEN Ran, FAN Xiao-fang, GONG Yong-sheng, MAO Sun-zhong. Changes of apoE protein expression in lung of mice with hypoxic pulmonary arterial hypertension [J]. CJAP, 2018, 34(6): 492-495.
[8]	ZHANG Cong-cong, ZHANG Jing-jing, CHEN Jun-hao, WU Yuan-ling, HUANG Dan-na, DAI Yong-yue, WANG Wan-tie. The effect of Yiqi Wenyang Huoxue Huatan Fang on hypoxia-hypercarbia induced pulmonary hypertension and its mechanism [J]. CJAP, 2018, 34(5): 408-413.
[9]	ZHANG Jing-jing, CHEN Jun-hao, ZHAO Mei-ping, WU Yuan-ling, ZHANG Cong-cong, YING Lei, CHEN Xi-wen, WANG Wan-tie. The role of endoplasmic reticulum stress in pulmonary hypertension in rat induced by chronic hypoxia and hypercapnia [J]. CJAP, 2018, 34(4): 327-333.
[10]	GUAN Jing-jing, ZHANG Ying, LIU Yu-jie. Effects of miRNA-1,miRNA-21 in plasma on in-stent restenosis in patients with coronary heart disease and diabetes mellitus after percutaneous coronary intervention [J]. CJAP, 2018, 34(4): 304-308.
[11]	MENG Han-yan, ZHAO Jie, HUA Chun-yan, ZHU Xing-yu, LI Yi-ling, YUAN Lin-bo. Improvement effects of applephenon on hypoxia pulmonary hypertension in rats by down-regulating the calcium sensing receptor [J]. CJAP, 2018, 34(3): 242-246.
[12]	CHEN Ran, JIANG Pu, LIU Ling-yan, GAO Yuan, YANG Xin-xin, CAI Zhuo-chang, FAN Xiao-fang, GONG Yong-sheng, MAO Sun-zhong. Apelin attenuates hypoxia induced pulmonary hypertension of mice through regulation of lipid metabolism [J]. CJAP, 2017, 33(6): 493-496.
[13]	HUANG Jun-xia, CHEN Zu-sheng, ZHANG Yang, ZHANG Kai, CHEN Yan-yan, CHEN Li-min, ZHOU Wei-wei. Establishment of rat model of type 2 diabetes complicated with hypertension [J]. CJAP, 2017, 33(4): 329-333.
[14]	WANG Chun-guang, LUO Xing-cai, YAO Tong, LIU Yu-yu, ZHAO She-hai, CHENG Jia-yuan, LI Yue, ZHAO Xiao-qi. Clinical value of DC and DRs in warning sudden cardiac death of patients with coronary artery disease [J]. CJAP, 2017, 33(3): 244-247.
[15]	WU Min, YANG Jing-ping, XU Xi-yuan, GUO Zhi-min, BU Bao-ying. Expressions of G2A and OGR1 in peripheral blood cells of patients with hypoxia induced pulmonary hypertension [J]. CJAP, 2017, 33(1): 85-88.